Fulcrum Therapeutics Shares Boosted by Positive Analyst Ratings

Fulcrum Therapeutics shares are trading higher after Piper Sandler raised its price target to $23 and H.C. Wainwright increased its target to $25, both maintaining positive ratings following promising PIONEER data.